The promising area of lipidomics has received a major interest as exploring panels of lipid biomarkers and their metabolic pathways might contribute to the early diagnosis of Alzheimer's disease allowing novel therapeutic targets. Dysfunctions in lipid metabolism have been associated with metabolic disorders as well as with aging and neurodegenerative diseases. Neurolipidomics is beginning to provide new insights into the pathophysiology of AD through identification of plasma and cerebral lipid mediators and metabolites (lipidome).
No takes yet. Share an insight, caveat, or question.
Efstathia et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: